DUBLIN, Ireland — Endo International plc has announced executive changes in its U.S. branded drug and research-and-development units. Endo said Patrick Barry has been appointed as senior vice president of U.S. branded pharmaceuticals effective immediately and Matthew Davis as senior vice president of R&D for branded pharmaceuticals effective Jan. 3. Barry, who comes to Endo
DUBLIN, Ireland — Endo International plc has appointed Paul Campanelli, as president and chief executive officer, succeeding Rajiv De Silva, who is stepping down. Endo said Campanelli, who was president of its generic drugs and OTC business, takes the helm as president and CEO effective immediately. With the move, he will take De Silva’s spot
DUBLIN, Ireland — Joseph Ciaffoni has been named president of U.S. branded pharmaceuticals at Endo International plc. Endo said Ciaffoni is slated to start in the new post on Aug. 15. He joins the company from Biogen, where he was senior vice president of the global specialty medicines group. “I am thrilled to be joining
DUBLIN, Ireland — Endo International plc has received an extension of its exclusive U.S. marketing rights for Voltaren Gel (diclofenac sodium topical gel 1%), a nonsteriodal anti-inflammatory drug (NSAID). Endo said Monday that it also was granted extended U.S. rights for the product’s authorized generic, should the company choose to launch it commercially in the future. Through an indirect
DUBLIN, Ireland — Endo International plc has completed its $8.05 billion acquisition of Par Pharmaceutical Holdings Inc. from leading global private investment firm TPG. Endo said Monday that with the closing of the deal, announced in May, its U.S. Generics segment that includes Par Pharmaceutical and Qualitest will be named Par Pharmaceutical, an Endo International
DUBLIN, Ireland — Endo International PLC plans to buy Par Pharmaceutical Holdings Inc. from TPG Capital North America in a deal valued at $8.05 billion. The pharmaceutical companies said Monday that the combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest-growing and among the top five by U.S.
LAVAL, Quebec, and RALEIGH, N.C. — Valeant Pharmaceuticals International Inc. has hiked its offer to buy Salix Pharmaceuticals, Ltd. under an amended agreement. The companies said Monday that Valeant boosted its cash offer to acquire all the outstanding common stock of Salix to $173 per share, or a total deal of about $15.8 billion, from $158